Northwestern Medicine Antimicrobial Continuous Renal Replacement Therapy Dosing Guidance

*** For acutely ill patients, consider usual dosing for the first 24 hours prior to adjusting for renal dysfunction ***

Antimicrobials			
Acyclovir	Ceftaroline	Ethambutol	Meropenem
Aminoglycosides	Ceftazidime	Fluconazole	Meropenem-vaborbactam
Ampicillin	Ceftazidime-avibactam	Flucytosine	Metronidazole
Ampicillin-sulbactam	Ceftolozane-tazobactam	Foscarnet	Micafungin**
Aztreonam	Cidofovir	Ganciclovir	Oseltamivir
Cefazolin	Ciprofloxacin	Imipenem	Penicillin G
Cefepime	Colistin	Imipenem-relebactam	Piperacillin-tazobactam
Cefiderocol	Daptomycin	Levofloxacin	TMP-SMX
Cefoxitin	Entecavir	Linezolid#	Vancomycin

Footnotes and References

Dosing protocol links:

- Renal Dosing Guidance (non CRRT)
- Aminoglycoside Dosing Protocol ‡ : Gram negative infections, Endocarditis Synergy, Cystic Fibrosis, Surgical Prophylaxis
- Agents not adjusted for renal function
- TDM Dosing Protocol
- HIV Antiretroviral Renal Adjustments

Instructions for using this Table:

1. In patients with no drug in their system, give an initial dose equal to that of a patient with normal renal function***
2. Determine the CRRT flow rate (the rate of Ultrafiltrate Fluid).
3. Add the Dialysate Flow rate to the Ultrafiltrate Flow rate.
4. Select the closest flow rate (e.g. 1 L/hr, 2 L/hr, etc).
5. Ensure that the patient's CRRT has not stopped unpredictably (e.g clotting, etc).

ADSP Northwestern Medicine Antimicrobial and Diagnostic Stewardship Program

Northwestern Medicine Antimicrobial Continuous Renal Replacement Therapy Dosing Guidance

Medication	Indications & Comments	Anephric Dose	1 L/Hr CRRT	2 L/Hr CRRT	3 L/Hr CRRT	4+ L/Hr CRRT
Acyclovir (AdjBW)	Standard dosing	5 mg/kg q24h	7.5 mg/kg q24h	5 mg/kg q12h	7.5 mg/kg q12h	10 mg/kg q12h
	Less severe mucocutaneous	2.5 mg/kg q24h	5 mg/kg q24h	5 mg/kg q24h	5 mg/kg q12h	5 mg/kg q12h
Aminoglycosides	Dose based on levels					
Ampicillin	Standard dosing	2 g q24h	2 g q8h	2 g q8h	2 g q8h Consider TDM	2 g q6h Consider TDM
	Endocarditis or meningitis	2 g q12h	2 g q8h	2 g q8h	2 g q6h Consider TDM	2 g q4h Consider TDM
Ampicillin-sulbactam	Standard dosing	3 g q24h	3 g q8h	3 g q8h	3 g q6h	3 g q6h
	Carbapenem Resistant *Acinetobacter baumanii*	3 g q12h Infused over 4 hours	3 g q8h infused over 4 hours	3 g q8h Infused over 4 hours	3 g q6h Infusion over 4 hours	3 g q6h infused over 4 hours
Aztreonam	Standard dosing	2 g q24h	1 g q8h	2 g q 12h	2 g q8h	2 g q8h
Cefazolin	Standard dosing	1 g q 24h or 2,2,3 g 3x weekly post-HD	1 g q8h	2 g q12h	2 g q8h	2 g q8h
Cefepime	Severe infections	1 g q 24h or 2 g 3x weekly post-HD	1 g q12h	1 g q8h Consider TDM	2 g q8h Consider TDM	2 g q8h Consider TDM
	Cystitis or less severe infections in patients <55kg or elderly (≥80 years)	1 g q 24h or 2 g 3x weekly post-HD	1 g q12h	1 g q8h Consider TDM	1 g q8h Consider TDM	2 g q8h Consider TDM
Cefiderocol	Standard dosing	750 mg q 12h	1.5 g q12h	2 g q12h	1.5 g q8h	2 g q8h
Cefoxitin	M. *abscessus* Dosing	1 g q24h	2 g q12h	2 g q12h	2 g q8h	2 g q8h
Ceftaroline*	Severe infection, bacteremia, osteo	200 mg q8h	400 mg q12h	300 mg q8h	400 mg q8h	400 mg q8h
Ceftazidime	Standard dosing	1 g q24h or 2,2,2 g 3x weekly post-HD	1 g q12h	2 g q12h	2 g q8h	2 g q8h
Ceftazidime-avibactam	Standard dosing	0.94 g q24h	1.25g q12h	2.5 g q12h	2.5 g q8h	2.5 g q8h
Ceftolozane-tazobactam	Standard dosing	750 mg q8h	1.5 g q8h	1.5 g q8h	3 g q8h	3 g q8h
Cidofovir (IBW)	Alternative dosing regardless of renal function for adenovirus or BK virus: 1 mg/kg 3x weekly without probenecid	5 mg/kg once weekly with probenecid and hydration	CrCl < 50: Risk vs benefit, discuss with ID team, consider 3 mg/kg once weekly			

ADSP Northwestern Medicine Antimicrobial and Diagnostic Stewardship Program

Northwestern Medicine Antimicrobial Continuous Renal Replacement Therapy Dosing Guidance

Medication	Indications & Comments	Anephric Dose	1 L/Hr CRRT	2 L/Hr CRRT	3 L/Hr CRRT	4+ L/Hr CRRT
Ciprofloxacin	Severe infection, *Pseudomonas,* and step-down therapy	400 mg q24h	400 mg q24h	400 mg q12h	400 mg q8h	400 mg q8h
	Less severe infections, UTI, prophylaxis	400 mg q24h	400 mg q24h	400 mg q12h	400 mg q12h	400 mg q12h
Colistin	For urinary source only, use polymyxin B IV for severe infections Polymyxin B does not require dose adjustment in CRRT	1.5 mg/kg q48h	Consult ID			
Daptomycin (AdjBW) (round to the nearest 250 mg, max dose of 1000 mg)	Severe *Staph* Infections	8 mg/kg 3x weekly post-HD	6-8 mg/kg q24h	8 mg/kg q24h	8 mg/kg q24h	8 mg/kg q24h
	Enterococcus infections	10 mg/kg 3x weekly post-HD	8-10 mg/kg q24h Consider twice weekly CK monitoring	10 mg/kg q24h	10 mg/kg q24h	10 mg/kg q24h
Entecavir		0.05-0.1 mg/day	0.1 mg/day	0.2 mg/day	0.3 mg/day	0.4 mg/day
Ethambutol (IBW)	See specific TB or NTM guidelines (round to the nearest 100 or 400 mg tablet)	15 or 25 mg/kg 3x weekly post-HD	15-20 mg/kg PO q24h Consider ID Consult			
Fluconazole	Disseminated infections	400 mg 3x weekly post-HD	800 mg x 1 then 400 mg q24h	800 mg q24h	800 mg q24h	800 mg q24h Consider 12 mg/kg load then 6 mg/kg q24h for patients > 120 kg
	Esophageal candidiasis	200 mg 3x weekly post-HD	200 mg q24h[$]			
	Prophylaxis	100 mg 3x weekly post-HD	100 mg q24h			
Flucytosine		25 mg/kg q48h	25 mg/kg q24h	25 mg/kg q12h	25 mg/kg q6h	25 mg/kg q6h
Foscarnet (AdjBW)		0 mg/kg/day	20 mg/kg/day	45 mg/kg/day	70 mg/kg/day	90 mg/kg/day
Ganciclovir	Induction	1.25 mg/kg q24h	2.5 mg/kg q24h	2.5 mg/kg q12h	3.75 mg/kg q12h	5 mg/kg q12h
	Maintenance	0.625 mg/kg q24h	1.25 mg/kg q24h	2.5 mg/kg q24h	3.75 mg/kg q24h	5 mg/kg q24h
Imipenem	Doses based on imipenem (500 mg)	500 mg q12h	500 mg q12h	500 mg q8h	500 mg q6h	1 g q8h
Imipenem-relebactam	1.25 g dose based on imipenem (500 mg) + cilastatin (500 mg) + relebactam (250 mg)	500 mg q6h	500 mg q6h	750 mg q6h	1 g q6h	1.25 g q6h

ADSP Northwestern Medicine Antimicrobial and Diagnostic Stewardship Program

Northwestern Medicine Antimicrobial Continuous Renal Replacement Therapy Dosing Guidance

Medication	Indications & Comments	Anephric Dose	1 L/Hr CRRT	2 L/Hr CRRT	3 L/Hr CRRT	4+ L/Hr CRRT
Levofloxacin	Standard dosing	750 mg x 1 then 500 mg q48h	750 mg x 1 then 250 mg q24h	750 mg x 1 then 500 mg q24h	750 mg q24h	750 mg q24h
Linezolid#	Standard dosing	600 mg q12h	600 mg q12h	600 mg q12h	600 mg q12h Consider 600 mg q8h in cases of MIC ≥ 2 mcg/mL or unknown in critical illness, CNS infections	
Meropenem	Systemic Infection (CNS, Sepsis, severe infections)	1 g q24h	500 mg q8h	1 g q8h	1 g q8h	1 g q8h 2 g q8h (CNS, pseudomonas)
Meropenem-vaborbactam	Doses based on combination	1 g q12h	1 g q8h	2 g q8h	2 g q8h	4 g q8h
Metronidazole	Standard dosing	500 mg q12h	500 mg q12h	500 mg q8h		
Micafungin**	Standard Dosing	100 mg q24h	CRRT or ECMO alone: 150 mg load x 1 then 100 mg q24h ECMO and CRRT: consider 200 mg load x 1 then 150 mg q24h			
Oseltamivir	Treatment	75mg x 1, then 30 mg 3x weekly post-HD	30 mg q24h	30 mg q12h	75 mg q12h	75 mg q12h
Penicillin G	Standard dosing	2 MU q8h	4 MU load then 2 MU q4h	4 MU q6h	4 MU q4h	4 MU q4h
Piperacillin-tazobactam	Standard dosing (4h infusion)	4.5 g q12h	4.5 g q12h	4.5 g q8h	4.5 g q8h	4.5 g q8h
TMP/SMX (AdjBW) Dose in mg based on TMP. Round PO doses to the nearest DS tab (160 mg)	Severe systemic infection	2.5 mg/kg q24h (max 320 mg)	5 mg/kg q24h	7.5 mg/kg q24h	5 mg/kg q12h	5 mg/kg q12h
	PJP Treatment	5 mg/kg q24h (max 320 mg)	7.5 mg/kg q24h	5 mg/kg q12h	5 mg/kg TMP q12h	5 mg/kg q8h (max 320 mg/dose)
Vancomycin (Round to the nearest 250 mg)	PharmD to Dose per AUC See Pharmacy Protocol	Dose per AUC	Provide loading dose 20-25 mg/kg then dose patient 10-15 mg/kg q24h and adjust based on levels			

Northwestern Medicine Antimicrobial Continuous Renal Replacement Therapy Dosing Guidance

Agents not renally adjusted:

- Amphotericin
- Azithromycin
- Baloxavir *(not studied in CrCl <50, but limited risk given single dose)*
- Ceftriaxone^
- Clindamycin
- Doxycycline
- Eravacycline
- Fosfomycin
- Itraconazole
- Isavuconazole
- Letermovir
- Linezolid#
- Maribavir
- Metronidazole
- Micafungin**
- Minocycline
- Molnupiravir
- Omadacycline
- Oxacillin/nafcillin
- Penicillin VK (PO
- Refer to Clinical Pharmacology for Polymyxin B Dosing
- Posaconazole
- Remdesivir
- Rifampin
- Tigecycline
- Voriconazole

Footnotes and References

† For obesity dosing, see Obesity Dosing for Weight-Based Antimicrobials

^ Although data do not suggest alterations in ceftriaxone clearance/half-life with CRRT, consideration for higher doses (e.g. 2 g q12h) may be warranted in cases of hypoalbuminemia. Most patients will *not* require increases in adjustment.

* Ceftaroline has been associated with clinically significant leukopenia. As data regarding CRRT flow rates is limited, particularly when >2 L/hr, closely monitor patient for signs and symptoms of toxicity

Linezolid dose adjustments to 600 mg q8h should be considered if MIC are ≥2 mcg/mL at high (>3 L/hr CRRT) in definitive, deep-seated infections (e.g CNS, endocarditis, undrained abscess) or initially when infections are suspected and risk of mortality is high

** Micafungin doses should be increased in clinically relevant indications (e.g. endocarditis, esophageal candidiasis, resistant organisms)

$ Loading doses of fluconazole should be utilized when clinically appropriate

Acronyms: HD = hemodialysis, PD = peritoneal dialysis, TMP/SMX = trimethoprim/sulfamethoxazole, MU = million units, URTI = upper respiratory tract infection, XR = extended release

For questions regarding this document (contact your primary pharmacist patient specific concerns) please contact: NMHPharmAntimicrobialStewardship@nm.org

Assembled by Michael Dickens, PharmD; Erin Weslander, PharmD, BCIDP, ID Pharmacist NMH; Christie Bertram, PharmD, BCIDP; Justin Moore, PharmD, BCPS, BCIDP; Sheila Wang, PharmD, BCPS-AQ-ID

Updated March 2023

Back to Top

References:

1. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159-66.
2. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562-77.
3. Ruiz J, Favieres C, Broch MJ, Villarreal E, Gordon M, Quinzá A, Castellanos Ortega Á, Ramirez P. Individualised antimicrobial dosing in critically ill patients undergoing continuous renal replacement therapy: focus on total drug clearance. Eur J Hosp Pharm. 2018 May;25(3):123-126. doi: 10.1136/ejhpharm-2016-001114. Epub 2017 Jan 13. PMID: 31157005; PMCID: PMC6452407.
4. Carlier M, Taccone FS, Beumier M, Seyler L, Cotton F, Jacobs F, Roberts JA. Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy. Int J Antimicrob Agents. 2015 Oct;46(4):413-9. doi: 10.1016/j.ijantimicag.2015.05.020. Epub 2015 Jul 6. PMID: 26208469.
5. Gatti M, Giannella M, Raschi E, Viale P, De Ponti F. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing. J Antimicrob Chemother. 2021 Jan 1;76(1):199-205. doi: 10.1093/jac/dkaa416. PMID: 33057628.
6. Goto K, Sato Y, Yasuda N, Hidaka S, Suzuki Y, Tanaka R, Kaneko T, Nonoshita K, Itoh H. Pharmacokinetics of ceftriaxone in patients undergoing continuous renal replacement therapy. J Basic Clin Physiol Pharmacol. 2016 Nov 1;27(6):625-631. doi: 10.1515/jbcpp-2016-0022. PMID: 27497425.
7. Soraluce A, Barrasa H, Asín-Prieto E, Sánchez-Izquierdo JÁ, Maynar J, Isla A, Rodríguez-Gascón A. Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation. Pharmaceutics. 2020 Jan 9;12(1):54. doi: 10.3390/pharmaceutics12010054. PMID: 31936614; PMCID: PMC7023070.
8. Barrasa H, Soraluce A, Isla A, Martín A, Maynar J, Canut A, Sánchez-Izquierdo JA, Rodríguez-Gascón A. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment. J Crit Care. 2019 Apr;50:69-76. doi: 10.1016/j.jcrc.2018.11.016. Epub 2018 Nov 17. PMID: 30496913.
9. Villa G, Di Maggio P, De Gaudio AR, Novelli A, Antoniotti R, Fiaccadori E, Adembri C. Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review. Crit Care. 2016 Nov 19;20(1):374. doi: 10.1186/s13054-016-1551-7. PMID: 27863531; PMCID: PMC5116218.
10. Cefiderocol. Package Insert. Shinogi September 2020.
11. Cain AR, Finoli LM, Guarascio A, Ogbebor O, Shively NR, Andrea T, Bremmer DN. Ceftaroline Pharmacokinetics in a Critically Ill Adult Receiving Continuous Venovenous Hemodiafiltration. Ann Pharmacother. 2022 Aug;56(8):965-966. doi: 10.1177/10600280211053868. Epub 2021 Oct 28. PMID: 34711073.
12. Kalaria S, Williford S, Guo D, Shu Y, Medlin C, Li M, Yeung SYA, Ali F, Jean W, Gopalakrishnan M, Heavner M. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy. 2021 Feb;41(2):205-211. doi: 10.1002/phar.2502. Epub 2021 Feb 7. PMID: 33438291.
13. Jaruratanasirikul S, Wongpoowarak W, Wattanavijitkul T, Sukarnjanaset W, Samaeng M, Nawakitrangsan M, Ingviya N. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7236-7244. doi: 10.1128/AAC.01669-16. PMID: 27671056; PMCID: PMC5119003.

14. Gao C, Tong J, Yu K, Sun Z, An R, Du Z. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration. Eur J Clin Pharmacol. 2016 Jul;72(7):823-30. doi: 10.1007/s00228-016-2045-x. Epub 2016 Mar 29. PMID: 27023465.
15. Zhang XS, Wang YZ, Shi DW, Xu FM, Yu JH, Chen J, Lin GY, Zhang CH, Yu XB, Tang CR. Efficacy and Pharmacodynamic Target Attainment for Ceftazidime-Avibactam Off-Label Dose Regimens in Patients with Continuous or Intermittent Venovenous Hemodialysis: Two Case Reports. Infect Dis Ther. 2022 Apr 8. doi: 10.1007/s40121-022-00621-z. Epub ahead of print. PMID: 35394640.
16. Soraluce A, Asín-Prieto E, Rodríguez-Gascón A, Barrasa H, Maynar J, Carcelero E, Soy D, Isla A. Population pharmacokinetics of daptomycin in critically ill patients. Int J Antimicrob Agents. 2018 Aug;52(2):158-165. doi: 10.1016/j.ijantimicag.2018.03.008. Epub 2018 Mar 20. PMID: 29572042.
17. Wenisch JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Dittrich P, Thalhammer F. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2012 Apr;67(4):977-83. doi: 10.1093/jac/dkr551. Epub 2011 Dec 29. PMID: 22210754.
18. Xie F, Li S, Cheng Z. Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy. J Antimicrob Chemother. 2020 Jun 1;75(6):1559-1566. doi: 10.1093/jac/dkaa028. PMID: 32083673.
19. Xu X, Khadzhynov D, Peters H, Chaves RL, Hamed K, Levi M, Corti N. Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy. Br J Clin Pharmacol. 2017 Mar;83(3):498-509. doi: 10.1111/bcp.13131. Epub 2016 Oct 28. PMID: 27628437; PMCID: PMC5306496.
20. Preiswerk B, Rudiger A, Fehr J, Corti N. Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Infection. 2013 Apr;41(2):553-7. doi: 10.1007/s15010-012-0300-3. Epub 2012 Jul 21. PMID: 22821405.
21. Rudiger A, Rentsch K, Maggiorini M, Corti N. Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care Med. 2011 May;39(5):1243-4; author reply 1244-5. doi: 10.1097/CCM.0b013e31820f6d58. PMID: 21610606.
22. Corti N, Rudiger A, Chiesa A, Marti I, Jetter A, Rentsch K, Müller D, Béchir M, Maggiorini M. Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy. Chemotherapy. 2013;59(2):143-51. doi: 10.1159/000353400. Epub 2013 Sep 18. PMID: 24051895.
23. Spooner AM, Deegan C, D'Arcy DM, Gowing CM, Donnelly MB, Corrigan OI. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. BMC Clin Pharmacol. 2011 Aug 4;11:11. doi: 10.1186/1472-6904-11-11. PMID: 21816053; PMCID: PMC3161942.
24. Roger C, Wallis SC, Louart B, Lefrant JY, Lipman J, Muller L, Roberts JA. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. J Antimicrob Chemother. 2016 Jun;71(6):1643-50. doi: 10.1093/jac/dkw043. Epub 2016 Mar 7. PMID: 26957490.
25. Onichimowski D, Wolska J, Ziółkowski H, Nosek K, Jaroszewski J, Czuczwar M. Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients - new assessment. Anaesthesiol Intensive Ther. 2020;52(4):267-273. doi: 10.5114/ait.2020.99605. PMID: 33165876.
26. Roberts DM, Liu X, Roberts JA, Nair P, Cole L, Roberts MS, Lipman J, Bellomo R; RENAL Replacement Therapy Study Investigators. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care. 2015 Mar 13;19(1):84. doi: 10.1186/s13054-015-0818-8. PMID: 25881576; PMCID: PMC4404619.
27. Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother. 2011 Dec;55(12):5868-73. doi: 10.1128/AAC.00424-11. Epub 2011 Sep 19. PMID: 21930888; PMCID: PMC3232768.

28. Sandaradura I, Marriott DJE, Day RO, Norris RLG, Pang E, Stocker SL, Reuter SE. Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. Eur J Clin Microbiol Infect Dis. 2021 Jul;40(7):1521-1528. doi: 10.1007/s10096-021-04201-w. Epub 2021 Feb 27. PMID: 33638727.
29. Karaiskos I, Friberg LE, Galani L, Ioannidis K, Katsouda E, Athanassa Z, Paskalis H, Giamarellou H. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2016 Sep;48(3):337-41. doi: 10.1016/j.ijantimicag.2016.06.008. Epub 2016 Jul 18. PMID: 27474468.
30. Horvatits T, Kitzberger R, Drolz A, Zauner C, Jäger W, Böhmdorfer M, Kraff S, Fritsch A, Thalhammer F, Fuhrmann V, Schenk P. Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. Antimicrob Agents Chemother. 2014;58(1):94-101. doi: 10.1128/AAC.00892-13. Epub 2013 Oct 21. PMID: 24145543; PMCID: PMC3910760.
31. Peng Y, Cheng Z, Xie F. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0082222. doi: 10.1128/aac.00822-22. Epub 2022 Aug 25. PMID: 36005753; PMCID: PMC9487629.
32. Thalhammer F, Horl WH: Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin Pharmacokinet 2000; 39:271–279
33. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2001 Oct;45(10):2949-54. doi: 10.1128/AAC.45.10.2949-2954.2001. PMID: 11557500; PMCID: PMC90762.
34. Shaw AR, Mueller BA. Antibiotic Dosing in Continuous Renal Replacement Therapy. Adv Chronic Kidney Dis. 2017 Jul;24(4):219-227. doi: 10.1053/j.ackd.2017.05.004. PMID: 28778361.
35. Rungkitwattanakul D, Chaijamorn W, Charoensareerat T, Charntrakarn P, Khamkampud O, Rattanaponpasert N, Srisawat N, Pattharachayakul S. Optimal levofloxacin dosing regimens in critically ill patients with acute kidney injury receiving continuous renal replacement therapy. J Crit Care. 2021 Jun;63:154-160. doi: 10.1016/j.jcrc.2020.09.018. Epub 2020 Sep 24. PMID: 33012583.
36. Garbez N, Mbatchi LC, Maseda E, Luque S, Grau S, Wallis SC, Muller L, Lipman J, Roberts JA, Lefrant JY, Roger C. A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. Ther Drug Monit. 2021 Dec 1;43(6):747-755. doi: 10.1097/FTD.0000000000000874. Erratum in: Ther Drug Monit. 2022 Apr 1;44(2):357. PMID: 33560097.
37. Vossen MG, Knafl D, Haidinger M, Lemmerer R, Unger M, Pferschy S, Lamm W, Maier-Salamon A, Jäger W, Thalhammer F. Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e02425-16. doi: 10.1128/AAC.02425-16. PMID: 28584142; PMCID: PMC5527635.
38. Tenorio-Cañamás T, Grau S, Luque S, Fortún J, Liaño F, Roberts JA. Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes. Ther Drug Monit. 2019 Jun;41(3):376-382. doi: 10.1097/FTD.0000000000000595. PMID: 30633087.
39. Cabanilla MG, Villalobos N. A successful daptomycin and micafungin dosing strategy in veno-venous ECMO and continuous renal replacement. J Clin Pharm Ther. 2022 Feb;47(2):251-253. doi: 10.1111/jcpt.13482. Epub 2021 Jul 13. PMID: 34254345.
40. López-Sánchez M, Moreno-Puigdollers I, Rubio-López MI, Zarragoikoetxea-Jauregui I, Vicente-Guillén R, Argente-Navarro MP. Pharmacokinetics of micafungin in patients treated with extracorporeal membrane oxygenation: an observational prospective study. Rev Bras Ter Intensiva. 2020 Jun;32(2):277-283. doi: 10.5935/0103-507x.20200044. Epub 2020 Jul 13. PMID: 32667449; PMCID: PMC7405733.
41. Watt KM, Cohen-Wolkowiez M, Williams DC, Bonadonna DK, Cheifetz IM, Thakker D, Benjamin DK Jr, Brouwer KLR. Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit. J Extra Corpor Technol. 2017 Sep;49(3):150-159. PMID: 28979038; PMCID: PMC5621578.

42. Eyler RF, Heung M, Pleva M, Sowinski KM, Park PK, Napolitano LM, Mueller BA. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy. 2012 Dec;32(12):1061-9. doi: 10.1002/phar.1151. PMID: 23208833.
43. Lemaitre F, Luyt CE, Roullet-Renoleau F, Nieszkowska A, Zahr N, Corvol E, Fernandez C, Antignac M, Farinotti R, Combes A. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. Ther Drug Monit. 2012 Apr;34(2):171-5. doi: 10.1097/FTD.0b013e318248672c. PMID: 22354159.
44. Curkovic I, Lüthi B, Franzen D, Ceschi A, Rudiger A, Corti N. Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration. Ann Pharmacother. 2010 Oct;44(10):1669-72. doi: 10.1345/aph.1P160. Epub 2010 Sep 7. PMID: 20823279.
45. Kesner JM, Yardman-Frank JM, Mercier RC, Wong CS, Walker SE, Argyres DP, Vilay AM. Trimethoprim and sulfamethoxazole transmembrane clearance during modeled continuous renal replacement therapy. Blood Purif. 2014;38(3-4):195-202. doi: 10.1159/000368884. Epub 2014 Dec 16. PMID: 25531772.
46. Covajes C, Scolletta S, Penaccini L, Ocampos-Martinez E, Abdelhadii A, Beumier M, Jacobs F, de Backer D, Vincent JL, Taccone FS. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Int J Antimicrob Agents. 2013 Mar;41(3):261-6. doi: 10.1016/j.ijantimicag.2012.10.018. Epub 2013 Jan 9. PMID: 23312601.
47. Kirwan M, Munshi R, O'Keeffe H, Judge C, Coyle M, Deasy E, Kelly YP, Lavin PJ, Donnelly M, D'Arcy DM. Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF). Crit Care. 2021 Dec 20;25(1):443. doi: 10.1186/s13054-021-03863-4. PMID: 34930430; PMCID: PMC8691013.
48. Xu X, Khadzhynov D, Peters H, Chaves RL, Hamed K, Levi M, Corti N. Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy. Br J Clin Pharmacol. 2017 Mar;83(3):498-509. doi: 10.1111/bcp.13131. Epub 2016 Oct 28. PMID: 27628437; PMCID: PMC5306496.